Science Friday (Free subscription) | 12 hours ago
The National Institutes of Health has decided to cancel a large-scale test of an experimental AIDS vaccine, saying that more focused research is needed on the way such vaccines interact with the immune system. The trial, known as PAVE 100, was designed to include more than 8,500 people.
Autism Vox (Free subscription) | yesterday
This is perhaps an example of medicine acting despite an absence of what we’d recognize as science, a case of peoples’ fears getting the better of them. This statement was made in reference to a “well-respected senior scientist” issuing a warning about cell phones being linked to cancer, as discussed in Ars Technica today. Other [...]
Fiercebiotech (Free subscription) | yesterday
> Merck's decision to pump $300 million into an expansion of its Durham, NC vaccine facility is seen by analysts as part of a coordinated effort to solidify a leading role in a booming global vaccines market. Report > Researchers are trying to find out why a vaccine for Alzheimer's would be able to eliminate the beta-amyloid plaque long considered responsible for the disease without actually curing...
Blog Posts about Irish TDs - (Free subscription) | yesterday
Minister for Health Mary Harney will today unveil new immunisation guidelines at the Royal College of Physicians of Ireland (RCPI) that recommend further vaccines for children.... Continue reading »
The Telegraph (Free subscription) | yesterday
More than £2 million worth of vaccines were wasted last year because they were allowed to go off, official figures show.
Genealogy@Bellaonline.com (Free subscription) | 07/24/2008
Accepting, foregoing, delaying or picking and choosing childhood vaccinations is an increasingly hot debate topic for parents and health practitioners. See how breastfeeding figures in to the decision-making process, how to find a vaccine-flexible doctor and resources you can consult to learn more.
Financial Time (Free subscription) | yesterday
Biotechnology group agrees to takeover as interest in vaccines grows
Market Watch (Free subscription) | yesterday
SAN FRANCISCO (MarketWatch) -- Sanofi Pasteur Holding, a vaccines division of Sanofi-Aventis , will buy United Kingdom's Acambis PLC for a total of about 276 million pounds ($549.5 million) or 190 pence a share, the pharmaceutical company said Friday. The offer price is a 65% premium to Acambis' share price of 115 pence at the close of business on July 24. Acambis is a London Stock Exchange-listed...
Treehugger (Free subscription) | yesterday
With the root cause of autism still only speculated upon, and everything from prescription drugs in the water supply to pesticides used to grow food and the manner in which vaccines are constructed potentially to blame, a new study shows socially aloof couples with a small circle of friends are more likely to parent autistic children. Suggesting genetics and the resulting social environment in which...
Medical News Today (Free subscription) | yesterday
As trials on anti-amyloid vaccines continue to fail in the search for a viable Alzheimer's drug, a new approach - oxidative stress - is starting to emerge as a contender. Anavex Life Sciences (AVXL.OB) is leading this promising avenue of research.
Investor's Iraq Forum (Free subscription) | yesterday
By Dennis L. Cuddy, Ph.D. http://www.newswithviews.com/Cuddy/dennis133.htm [Note: While there has been increasing attention paid to the linkage between vaccines and autism, practically no attention has been paid to the possible linkage between the flu vaccine and Alzheimer's. Dr. H. H....
Red Orbit (Free subscription) | 07/24/2008
Dynavax Technologies has signed an agreement with Novartis Vaccines and Diagnostics for the supply and development, and possible commercialization, of Dynavax's novel universal influenza vaccine in collaboration with Novartis.
ireland.com (Free subscription) | 07/24/2008
Minister for Health Mary Harney will today unveil new immunisation guidelines at the Royal College of Physicians of Ireland (RCPI) that recommend further vaccines for children.
The Washington Business Journal (Free subscription) | 07/24/2008
Emergent BioSolutions Inc. has received two federal grants worth more than $4.5 million to continue development on two vaccines. (EBS)
Baltimore Sun (Free subscription) | 07/24/2008
Baltimore's Theradigm Inc., which is attempting to make treatments for central nervous system disorders, and Frederick's APE-BridgePath Scientific, which works in preclinical development of drugs and vaccines, are the first companies to receive funds from a $750,000 pool of money secured in September. Each got $50,000.
